Acute myeloid leukemia, or AML, is a type of cancer that affects the bone marrow and blood. Learn about outlook and survival rates for this cancer.

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that largely affects older adults. Discover the causes, risk factors, how it’s classified, and more information like on ...

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common pediatric cancers and among the leading causes of death in children. Apr 30, 2025 0 ...

In this study, 1557 patients with untreated acute myeloid leukemia were given induction chemotherapy. Consolidation therapy, including the use of stem cell transplant, was based on a risk-adapted ...

Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present the data obtained from 2345 acute leukemia ...

Eunice Wang, MD, chief of leukemia at Roswell Park, will present Phase 1B/2 results of the KOMET-001 study (NCT04067336) during an oral abstract session Monday, June 2, at the American Society of ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase ...

FDA Reviews Kura's NDA For Ziftomenib To Treat Acute Myeloid Leukemia With NPM1 Mutation June 01, 2025 — 09:13 pm EDT Written by RTTNews.com for RTTNews -> ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...

Potential Positives. The first patient has been dosed in the Phase 1 clinical trial of CER-1236, marking a significant milestone in the development of this novel therapy for acute myeloid leukemia ...

Kura Oncology’s ziftomenib addresses a specific genetic mutation present in about 30% of cases of acute myeloid leukemia. Data from the drug’s pivotal Phase 2 test were presented during the ...